The Barriers Limiting Radiopharmaceutical Access
September 21, 2026
From isotope supply to reimbursement, the practical challenges shaping real-world delivery in oncology
5 min read
False
Advertisement
Interviews
Musings from The Power List: Dajun Yang
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
What Do Scientists Want from AI?
September 14, 2026
Scientists are already using AI in the lab – but many are doing so without the safeguards their employers may assume are in place
5 min read
Musings from The Power List: Ali Tavassoli
By Ali Tavassoli
September 10, 2026
Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology
8 min read
The Manufacturing Questions Facing Chinese Biotech
September 9, 2026
Lonza’s Wayne Wen discusses the growing maturity of China’s drug development and manufacturing ecosystem – and what companies need to compete internationally
5 min read
Musings from The Power List: Miguel Forte
By Miguel Forte
September 8, 2026
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
4 min read
Musings from The Power List: Peng Lu
September 4, 2026
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
2 min read
China’s Biopharma Homecoming
By James Strachan, Henry Thomas
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
Musings from The Power List: Christine Allen
By Christine Allen
August 28, 2026
Christine Allen believes AI will connect every stage of drug development, but only if it remains guided by human expertise
2 min read
Green Shoots, Gray Skies
By Olivia Anderson, James Strachan
August 26, 2026
Jon Rees sees signs of recovery following biotech's post-pandemic funding reset, but there’s no going back to the “old normal”
9 min read
